Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 142840
Corporate User License Price USD 6000
Corporate User License Price INR 428520
Site License Price USD 4000
Site License Price INR 285680
Request a Quote

Report Title

Hepatitis D-Pipeline Review, H1 2015

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Hepatitis D-Pipeline Review, H1 2015


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Hepatitis D-Pipeline Review, H1 2015

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Hepatitis D-Pipeline Review, H1 2015



Executive Summary

Hepatitis D-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Hepatitis D-Pipeline Review, H1 2015', provides an overview of the Hepatitis D's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hepatitis D, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis D and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Hepatitis D

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Hepatitis D and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Hepatitis D products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Hepatitis D pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Hepatitis D

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Hepatitis D pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Hepatitis D Overview 6

Therapeutics Development 7

Pipeline Products for Hepatitis D-Overview 7

Pipeline Products for Hepatitis D-Comparative Analysis 8

Hepatitis D-Therapeutics under Development by Companies 9

Hepatitis D-Pipeline Products Glance 10

Clinical Stage Products 10

Early Stage Products 11

Hepatitis D-Products under Development by Companies 12

Hepatitis D-Companies Involved in Therapeutics Development 13

Alnylam Pharmaceuticals, Inc. 13

BioDiem Ltd 14

Biogenomics Limited 15

Eiger BioPharmaceuticals, Inc. 16

Globeimmune, Inc. 17

Johnson & Johnson 18

REPLICor Inc. 19

SomaGenics Inc. 20

Hepatitis D-Therapeutics Assessment 21

Assessment by Monotherapy Products 21

Assessment by Target 22

Assessment by Mechanism of Action 24

Assessment by Route of Administration 26

Assessment by Molecule Type 28

Drug Profiles 30

ALN-HDV-Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

EBP-921-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

GI-18000-Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

hepatitis D vaccine-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

interferon alfa-2b (recombinant)-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

lonafarnib-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Myrcludex-B-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

REP-9-AC'-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

RNAi Oligonucleotide for Hepatitis D-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

tipifarnib-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

Hepatitis D-Recent Pipeline Updates 43

Hepatitis D-Product Development Milestones 46

Featured News & Press Releases 46

Apr 13, 2015: Eiger BioPharmaceuticals Announces Abstracts and Presentations of Lonafarnib Data in Hepatitis Delta at the European Association for the Study of the Liver Conference-April 22 to 26, 2015 46

Apr 10, 2015: Replicor to Present at the 2015 Lancet Viral Hepatitis Conference 46

Apr 02, 2015: Replicor Announces Completion of Enrollment in Phase II Trial 46

Feb 23, 2015: Eiger BioPharmaceuticals Announces Presentation of Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib 47

Dec 22, 2014: Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib-Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 47

Dec 22, 2014: Eiger Bio Receives Orphan Designation for Lonafarnib, a First In Class, Investigational Treatment for Hepatitis Delta Virus (HDV) Infection 48

Oct 01, 2014: REPLICor announces initiation of its Phase II clinical trial with REP 2139-Ca in combination with Pegasys in patients with hepatitis B / hepatitis D co-infection 48

Appendix 49

Methodology 49

Coverage 49

Secondary Research 49

Primary Research 49

Expert Panel Validation 49

Contact Us 49

Disclaimer 50

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Tables

Number of Products under Development for Hepatitis D, H1 2015 7

Number of Products under Development for Hepatitis D-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Comparative Analysis by Clinical Stage Development, H1 2015 10

Comparative Analysis by Early Stage Development, H1 2015 11

Products under Development by Companies, H1 2015 12

Hepatitis D-Pipeline by Alnylam Pharmaceuticals, Inc., H1 2015 13

Hepatitis D-Pipeline by BioDiem Ltd, H1 2015 14

Hepatitis D-Pipeline by Biogenomics Limited, H1 2015 15

Hepatitis D-Pipeline by Eiger BioPharmaceuticals, Inc., H1 2015 16

Hepatitis D-Pipeline by Globeimmune, Inc., H1 2015 17

Hepatitis D-Pipeline by Johnson & Johnson, H1 2015 18

Hepatitis D-Pipeline by REPLICor Inc., H1 2015 19

Hepatitis D-Pipeline by SomaGenics Inc., H1 2015 20

Assessment by Monotherapy Products, H1 2015 21

Number of Products by Stage and Target, H1 2015 23

Number of Products by Stage and Mechanism of Action, H1 2015 25

Number of Products by Stage and Route of Administration, H1 2015 27

Number of Products by Stage and Molecule Type, H1 2015 29

Hepatitis D Therapeutics-Recent Pipeline Updates, H1 2015 43

List of Figures

Number of Products under Development for Hepatitis D, H1 2015 7

Number of Products under Development by Companies, H1 2015 9

Comparative Analysis by Early Stage Products, H1 2015 11

Assessment by Monotherapy Products, H1 2015 21

Number of Products by Top 10 Targets, H1 2015 22

Number of Products by Stage and Top 10 Targets, H1 2015 23

Number of Products by Top 10 Mechanism of Actions, H1 2015 24

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 25

Number of Products by Top 10 Routes of Administration, H1 2015 26

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 27

Number of Products by Top 10 Molecule Types, H1 2015 28

Number of Products by Stage and Top 10 Molecule Types, H1 2015 29

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Alnylam Pharmaceuticals, Inc.

BioDiem Ltd

Biogenomics Limited

Eiger BioPharmaceuticals, Inc.

Globeimmune, Inc.

Johnson & Johnson

REPLICor Inc.

SomaGenics Inc.

Hepatitis D Therapeutic Products under Development, Key Players in Hepatitis D Therapeutics, Hepatitis D Pipeline Overview, Hepatitis D Pipeline, Hepatitis D Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand